XENiOS

What XENiOS does

Xenios AG, headquartered in Heilbronn, Germany, is a medical device company specializing in extracorporeal life support (ECLS) technologies, principally extracorporeal membrane oxygenation (ECMO) systems used to treat critically ill patients with cardiac and/or pulmonary failure. The company's core product is the Xenios Console (marketed as XENIOS 2.0), a unified hardware platform that integrates multiple treatment profiles—adult ECMO, pediatric and neonatal ECMO, synchronized cardiac support (SCS), and extracorporeal CO2 removal (ECCO2R)—on a single console. Supporting components include the DP3 pump drive with battery backup, the Sensorbox, age-specific gasblenders, and the MultiSupport GROUND transport solution, complemented by preconfigured patient kits containing oxygenators certified for application periods of up to 29 days. The company is recognized as a specialist in ECMO treatment and is mentioned among leading players in adjacent perfusion and heart-lung machine markets.

Xenios operates as a wholly-owned subsidiary of Fresenius Medical Care, the world's leading provider of products and services for people with renal diseases, having been acquired at the end of 2016. Its business model combines capital equipment sales (consoles) with a recurring consumables stream (patient kits and oxygenators used in acute and chronic heart and lung failure treatment). Distribution is enterprise-direct to hospitals, intensive care units, and specialized ECMO centers globally, with a stated geographic exclusion of the United States. The company supports clinical adoption through the Heart & Lung Campus e-learning platform and active engagement at major medical congresses (e.g., EuroELSO, ISICEM, EACTS, ESPNIC, ESICM LIVES). Customer relationships are structured around institutional procurement, quote-based pricing, and recurring consumable replenishment for ongoing ECMO/ECLS programs.

Name

XENiOS

Legal name

Xenios AG

Website

https://xenios-ag.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

251–500 employees

Short description

Xenios AG develops and markets extracorporeal life support (ECMO/ECLS) systems, including the Xenios Console and patient kits, for hospitals and critical care units treating patients with cardiac and pulmonary failure. It operates as a subsidiary of Fresenius Medical Care.

Ownership category

akta.pro rank

Product category

Extracorporeal Life Support Systems

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industry

Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC) (HLAHAGAD)

Keywords

• Extracorporeal life support
• ECMO therapy systems
• Cardiopulmonary medical devices
• Critical care equipment
• Oxygenator consumables

Headquarters

HQ city

Heilbronn

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. ECMO/ECLS Systems and Consoles: Sale of the Xenios console platform and related hardware to hospitals and healthcare facilities for critical care and ECMO treatments.
2. Patient Kits and Consumables: Preconfigured patient kits containing oxygenators and related consumables certified for up to 29-day application periods. These represent recurring revenue from consumables replenishment.
3. ECMO Systems and Services: Active in the ECMO market with strategic partnerships and continuous product innovation, pursuing market leadership in the critical care extracorporeal life support segment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Xenios AG develops, manufactures, and sells extracorporeal life support (ECLS) and extracorporeal membrane oxygenation (ECMO) systems for hospitals treating patients with cardiac and/or pulmonary failure. Its core offering is the XENIOS 2.0 console platform, which combines cardiac and pulmonary support on a single technological platform, complemented by preconfigured patient kits containing oxygenators certified for application periods up to 29 days, plus a ground transport solution for mobile ECMO delivery.

Product overview

Xenios AG offers a unified extracorporeal life support platform called XENIOS 2.0, which combines cardiac and pulmonary support on a single technological console. The core platform integrates multiple treatment options including ECMO, Pediatric ECMO, Synchronized Cardiac Support, and ECCO2R. The ecosystem includes the Xenios Console (multifunctional hardware system), Patient Kits with integrated oxygenators (certified for up to 29 days), and components such as the Sensorbox, DP3 Pump Drive with backup, and Gasblenders for adult/pediatric use. A MultiSupport GROUND transport solution enables mobile treatment delivery. The company also provides the Heart & Lung Campus as an educational service platform. All products are designed for critical care patients requiring extracorporeal support due to cardiac and/or pulmonary failure.

Differentiator

Problem solved

Functional benefit

Products and services

• Xenios Console (XENIOS 2.0) A multifunctional extracorporeal life support (ECLS) console that combines different treatment profiles — including ECMO, pediatric ECMO, synchronized cardiac support, and ECCO2R — on one single technical platform. Supports gas exchange in the lungs and cardiovascular system for hospitals treating critically ill patients with cardiac and/or pulmonary failure.
• Patient Kits Preconfigured patient kits containing oxygenators in different sizes, certified for application periods of up to 29 days, used to treat acute and chronic heart and lung failure. Sold as recurring consumables to hospitals alongside the Xenios console.
• MultiSupport GROUND Transport Solution A transport solution that enables mobile ECMO/ECLS treatment during patient ground transport, extending extracorporeal life support delivery beyond the hospital setting.
• Heart & Lung Campus An online e-learning and training platform offering expert interviews, best-practice cases, medical information, hands-on tutorials, and priming instructions, available on-demand 24/7 for healthcare professionals using Xenios products.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• EuroELSOminorGTM or Marketing PartnerEuroELSO (European Extracorporeal Life Support Organization) is listed as a partner on the Xenios website. EuroELSO is a professional medical organization focused on ECMO and ECLS education and research. Xenios participates in EuroELSO congresses and maintains a partnership for industry engagement and medical community outreach.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Getinge (Maquet): Getinge's Maquet brand is one of the global leaders in cardiopulmonary bypass and ECMO/ECLS consoles and disposables. It competes head-to-head with Xenios in European hospitals on heart-lung machine and oxygenator share.
• LivaNova: LivaNova's Cardiopulmonary business (formerly Sorin) manufactures heart-lung machines, oxygenators, and ECMO consumables. It is a direct competitor in extracorporeal circulation equipment and disposables for cardiac surgery and ECLS.
• Terumo: Terumo (Terumo Cardiovascular / Terumo BCT) produces heart-lung machines, oxygenators, and ECMO/ECLS systems. It is a direct peer in the perfusion and extracorporeal life support device market globally.
• Eurosets: Eurosets is an Italian manufacturer of ECMO and ECLS devices, oxygenators, and cardiopulmonary equipment. It is a direct peer to Xenios in the European ECMO console and disposable market.

Broad incumbents

• Medtronic: Medtronic's Cardiac Surgery / Mechanical Circulatory Support portfolio includes perfusion and oxygenation products. As a broad incumbent with deep U.S. presence, it competes with Xenios for hospital critical-care accounts.
• Abbott: Abbott's cardiovascular portfolio includes mechanical circulatory support devices and is a broad incumbent in the cardiac critical-care space, overlapping with Xenios in ECLS-adjacent accounts and hospital contracts.
• Nipro: Nipro's Medical Devices segment produces hollow-fibre oxygenators and ECMO/ECLS disposables, competing with Xenios's patient kit and oxygenator business in selected international markets.

Emerging players

• Inspira Technologies: Inspira Technologies is developing next-generation extracorporeal respiratory support systems (e.g., ART device). It is an emerging player aiming to compete in the ECLS / oxygenation category where Xenios operates.
• CytoSorbents: CytoSorbents develops extracorporeal blood purification therapies used in critical-care settings (e.g., CytoSorb for cytokine removal). It is an emerging adjacent player in extracorporeal therapies that increasingly overlap with ECLS workflows.

Others

• Fresenius Medical Care: Xenios's parent company and a strategic partner in the Critical Care multi-organ support franchise. Fresenius is adjacent rather than directly competitive, providing renal and acute-care products that complement Xenios's ECMO/ECLS portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/ecls_fmc_ag?lang=de
• YouTubeyoutube.com/channel/UCVhG0xJgXDz9YxYs0r8y0vA
• LinkedInlinkedin.com/company/xenios-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XENiOS